Combined intravenous immunoglobulin and baricitinib treatment for severe COVID-19 with rhabdomyolysis: A case report

[1]  Jann-Yuan Wang,et al.  Successful treatment of a critical COVID-19 patient with tocilizumab , 2020, Journal of the Formosan Medical Association.

[2]  Urvish K. Patel,et al.  Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis , 2020, BMJ Evidence-Based Medicine.

[3]  Jennifer L. Bell,et al.  Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report , 2020, medRxiv.

[4]  Shakiba Darvishalipour,et al.  COVID-19: combining antiviral and anti-inflammatory treatments , 2020 .

[5]  M. Corbellino,et al.  Baricitinib for COVID-19: a suitable treatment? – Authors' reply , 2020, The Lancet Infectious Diseases.

[6]  R. Caporali,et al.  Baricitinib for COVID-19: a suitable treatment? , 2020, The Lancet Infectious Diseases.

[7]  Lei Liu,et al.  The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients , 2020, Inflammation Research.

[8]  Yuntao Wu,et al.  Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools , 2020, Virologica Sinica.

[9]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[10]  P. Mehta,et al.  COVID-19: consider cytokine storm syndromes and immunosuppression , 2020, The Lancet.

[11]  K. Yuen,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.

[12]  Yan Zhao,et al.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.

[13]  Gengfu Xiao,et al.  Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro , 2020, Cell Research.

[14]  A. Phelan,et al.  Baricitinib as potential treatment for 2019-nCoV acute respiratory disease , 2020, The Lancet.

[15]  Ting Yu,et al.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.

[16]  W. Cao,et al.  Hypothesis for potential pathogenesis of SARS-CoV-2 infection–a review of immune changes in patients with viral pneumonia , 2020, Emerging microbes & infections.

[17]  M. Genovese,et al.  Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment , 2018, The Journal of Rheumatology.

[18]  Ivan K. Chinn,et al.  Update on the use of immunoglobulin in human disease: A review of evidence , 2017, The Journal of allergy and clinical immunology.

[19]  M. Dougados,et al.  Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study , 2016, Annals of the rheumatic diseases.

[20]  A. Kaye,et al.  Rhabdomyolysis: pathogenesis, diagnosis, and treatment. , 2015, Ochsner Journal.

[21]  Mario F. Fadila,et al.  Rhabdomyolysis Secondary to Influenza A Infection: A Case Report and Review of the Literature , 2015, North American journal of medical sciences.

[22]  Chong-Jen Yu,et al.  Clinical Manifestations, Laboratory Findings, and Treatment Outcomes of SARS Patients , 2004, Emerging infectious diseases.

[23]  J. Seiler,et al.  Influenza A Induced Rhabdomyolysis Resulting in Extensive Compartment Syndrome , 2000, Clinical orthopaedics and related research.

[24]  A. Knutsen,et al.  Rhabdomyolysis and lower extremity compartment syndrome due to influenza B virus. , 1993, Annals of plastic surgery.